Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome

Hormone and Metabolic Research

Volumn 34, Issue 11-12, 2002, Pages 616-621

  Wajchenberg, B L ^a   Giannella Neto, D ^a   Da Silva, M E R ^a   Santos, R F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adipose Tissue; Insulin Resistance; Metabolic Syndrome; Obesity; Subcutaneous (SAT); Visceral (VAT)

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; FATTY ACID; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOSE TISSUE; BODY MASS; DYSLIPIDEMIA; HORMONAL REGULATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC REGULATION; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS FAT;

ADIPOSE TISSUE; BODY COMPOSITION; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; OBESITY; SEX CHARACTERISTICS; SUBCUTANEOUS TISSUE; TISSUE DISTRIBUTION; VISCERA;

EID: 0036875205     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-38256     Document Type: Review

References (41)

1. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738
2. Alberti KGMM, Zimmet PZ (for the WHO Consultation). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
3. Montague CT, O'Rahilly S. The perils of portliness. Causes and consequences of visceral adiposity. Ann Rev Diabetes 2001; 49: 1-8
4. Smith SR, Lovejoy JC, Greenway F, Ryan D, deJonge L, de la Bretonne J, Volafova J, Bray GA. Contribution of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001; 50: 426-435
5. Tchkonia T, Karagiannides I, Forse RA, Kirkland JL. Different fat depots are distinct mini-organs. Current Opin Endocrinol Diabetes 2001; 8: 227-234
6. Smith SR, Zachwieja JJ. Visceral adipose tissue: a critical review of intervention strategies. Int J Obes 1999; 23: 329-335
7. Engfeldt P, Arner P. Lipolysis in human adipocytes. Effects of cell size, age and of regional differences. Horm Metab Res Suppl. 1988; 19: 26-29
8. Martin ML, Jensen MD. Effects of body fat distribution on regional lipolysis in obesity. J Clin Invest 1991; 88: 609-613
9. Guo Z, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999; 48: 1586-1592.
10. Frayn KN. Visceral fat and insulin resistance - causative or correlative? Brit J Nutrit 2000; 83 Suppl. 1: S71-S77
11. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229
12. Rebuffé-Scrieve M, Bronnegard M, Nilsson A, Eldh J, Gustafsson J-A, Björntorp P. Steroid hormone receptors in human adipose tissue. J Clin Endocrinol Metab 1990; 71: 1215-1219
13. Fried SK, Russell CD, Grauso NL, Brolin RE. Lipoprotein lipase regulation by insulin and glucocorticoids in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 1993; 92: 2191-2198
14. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997; 349: 1210-1213.
15. Elmquist JK. CNS regulation of energy balance and body weight: insights from rodent models. Lab Anim Sci 1998; 48: 630-637
16. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocr Metab 2000; 11: 327-332
17. Monokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-343
18. Kamon J, Yamauchi T, Waki H, Uchida SK, Ito Y, Suzuki R, Aoyama M, Takasawa K, Kubota N, Terauchi Y, Tobe K, Kadowaki T. Mechanism for the regulation of adiponectin expression. Diabetes 2002; 51 (Suppl. 2): A351
19. Yang W-S, Jeng C-Y, Wu T-J, Tanaka S, Funahashi T, Matsuzawa Y, Wang J-P, then C-H, Tay T-Y, Chuang L-M. Synthetic peroxysome proliferator activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care: 2002; 25: 376-380
20. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hipoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
21. Ito Y, Yamauchi T, Waki H, Kamon J, Uchida S, Kimura S, Kadowaki T. Direct effects of adiponectin on skeletal muscle. Diabetes 2002; 51 Suppl. 2: A1868
22. Yamauchi T, Kamon J, Terauchi Y, Kubota N, Waki H, Mori Y, Hara K, Akanuma Y, Kimura S, Tobe K, Yoda M, Tomita M, Froguel P, Kadowaki T. Replenishment of fat-derived hormone adiponectin reverses insulin resistance in lipoatrophic diabetes and type 2 diabetes. Diabetes 2001; 50 Suppl. 2: A282
23. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
24. McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87: 2407-2410
25. Engeli S, Sharma AM. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Horm Metab Res 2000; 32: 485-499
26. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease; is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214
27. Päth G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997; 82: 2343-2349
28. Sethi J, Hotamisligil GS. The role of TNFα in adipocyte metabolism. Semin Cell Dev Biol 1999; 10: 19-29
29. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of Plasminogen activator inhibitor-1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867
30. Niesler CU, Siddle K, Prins JB. Human preadipocytes display lower depot-specific susceptibility to apoptosis. Diabetes 1998; 47: 1365-1368
31. Caserta F, Tchkonia T, Civelek VN, Prentki M, Brown NF, McGarry JD, Forse RA, Corkey BE, Hamilton JA, Kirkland JL. Fat depot origin affects fatty acid handling in cultured rat and human preadipocytes. Am J Physiol Endocrinol Metab 2001; 280: E238-E247
32. Tchkonia T, Giorgadze N, Pirtskhalava T, Tchoukalova Y, Karagiannides I, Forse RA, DePonte M, Stevenson M, Guo W, Han J, Waloga G, Lash TL, Jensen MD, Kirkland JL. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipoocytes. Am J Physiol Regul Integr Comp Physiol 2002; 82: 1286-1296
33. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Sewter CP, Digby JE, Lazar ME, Chatterjee VKK, O'Rahilly S. Activators of PPARγ have depot-specific effects on human pre-adipocyte differentiation. J Clin Invest 1997; 100: 3149-3153
34. Kelly I, Han T, Walsh K, Lean M. Effects of thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293
35. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47: 699-713
36. Rönnemaa T, Koskenvuo M, Marniemi J, Koivunen T, Sajantila A, Rissanen A, Kaitsaari M, Bouchard C, Kaprio J. Glucose metabolism in identical twins discordant for obesity. The critical role of visceral fat. J Clin Endocrinol Metab 1997; 82: 383-387
37. Lemieux S, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Desprès JP. Seven-year changes in body fat and visceral adipose tissue in women. Diabetes Care 1996; 19: 983-991
38. Marks SJ, Moore NR, Clark MI, Strauss BJG, Hockaday TDR. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 1996; 4: 1-7
39. Kelley DE, Williams KV, Price JC, McKolanis TM, Goodpaster BH, Thaete FL. Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 5412-5419
40. Abate B, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995; 96: 88-98
41. Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579-1585